Insiders Aren’t Buying Pfizer Stock, and That Could Help
Pfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
Expense ratio components for Dividend Aristocrats ETFs include management fees and other ongoing costs that reduce net returns.
20,481 articlesPfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
Strategy transferred 411.48 BTC to Coinbase on May 29, 2026, a tiny slice of its huge stake. The move sparks renewed ...
With housing payments rising and rates lingering near multi-year highs, five categories of monthly dividend investmen...
Cash flow from senior housing and warehouse REITs is holding steady even as refinancing costs rise. The payout outloo...
NVIDIA leads the AI chip market with strong cash returns, while Intel pursues a turnaround with a cautious growth pro...
With market volatility on the rise, investors are turning to high-yield dividend plays. Three U.S. names stand out fo...
As markets enter the midyear phase of 2026, three proven compounders highlight why patient investing still works. App...
A Tuesday pullback in COP shares left investors weighing oil prices, broker notes, and the long-term outlook for ener...
A celebrity DM moment becomes a smart-money lesson. This article uses the idea of erling haaland finally accepts an i...
A Hong Kong-based firm disclosed a $436 million stake in BlackRock’s IBIT, highlighting how offshore capital channels...
Vanguard’s latest outlook suggests international equities may outperform U.S. stocks over the coming decade. This art...
From repeated loan denials to a growing 10+ unit multifamily portfolio, this deal diary-style story reveals the strat...